Discover MacuMira, a clinically proven technology approved by Health Canada. It uses a device that delivers a microcurrent through closed eyes to target retinal cells and slow the progression of age-related dry macular degeneration (AMD).
It’s for me if…
I have early to intermediate age-related dry macular degeneration.
Contraindications
This treatment should be avoided if you have a pacemaker, a cochlear implant, or if you suffer from severe or uncontrolled glaucoma, multiple sclerosis, or epilepsy.
Initial duration
4 sessions of 32 minutes for the first 10 days.
Cost
500 $ per session.
Prix valide jusqu’au 31 décembre 2026.
MacuMira is the only treatment currently available on the market for age-related dry macular degeneration. This painless technology aims to slow the progression of the condition by acting directly on the cells of the retina to stimulate their regeneration.
Microcurrent stimulation sends pulses through closed eyelids, cleansing the retina and improving visual function in patients with dry macular degeneration.
Retrouvez une vision plus claire et ne laissez pas les symptômes affecter votre qualité de vie. Schedule an appointment with one of our professionals today and discover MacuMira technology. Schedule an appointment with one of our professionals today and discover MacuMira technology.
AMD is an eye disease that mainly affects people over the age of 50. It manifests itself through the progressive deterioration of the macula, a central area of the retina responsible for sharp vision and color perception.
Over time, AMD can cause a decline in central vision, making it more difficult to read, recognize faces, and drive.
MacuMira uses microcurrent stimulation, a non-invasive technology that supports retinal health. By applying very low electrical currents through the eyelids, the device stimulates retinal cells, promoting their repair and functioning.
A typical treatment involves wearing the device for about 30 minutes at an eye care professional’s office, without injections or surgery.
No, MacuMira treatment is painless and has no known risks. It does not require injections, medication, or lasers: the patient simply wears a device over their eyes during the session.
Clinical studies have reported no adverse effects, and patients often notice improvements in their vision within the first few weeks.
Clinical studies show that most patients treated with MacuMira experience improved central vision, better contrast perception, and an enhanced quality of life. These gains typically become apparent after a few sessions and are maintained over time, as long as the treatment is continued.
